Global Information
회사소개 | 문의 | 비교리스트

세계의 리소좀 축적질환 시장(2020-2026년)

Lysosomal Storage Disease Market 2020-2026

리서치사 Orion Market Research Pvt Ltd
발행일 2020년 06월 상품 코드 949614
페이지 정보 영문
가격
US $ 3,600 ₩ 4,254,000 Unprintable PDF (Single User License)
US $ 4,800 ₩ 5,672,000 Printable PDF (Enterprise License)


세계의 리소좀 축적질환 시장(2020-2026년) Lysosomal Storage Disease Market 2020-2026
발행일 : 2020년 06월 페이지 정보 : 영문

리소좀 축적질환 시장은 예측기간(020년-2026년) 중에 상당한 CAGR로 성장하면 예측됩니다. 시장 성장을 촉진하는 요인에는 질환 진단 비율, 질환에 대한 인식 및 헬스케어 부문 연구개발 증가가 있습니다. 질환 진단은 개인에 따라서 증상이 다르기 때문에 의사에게는 곤란하지만, 연구개발 증가에 의해 질환 진단이 개선되고 있습니다. 질환을 진단하기 위해서 특정 검사를 실시할 수 있는 전문 리소좀 축적질환 연구소가 있습니다. 이 또한 시장 성장을 뒷받침하고 있습니다.

리소좀 축적질환 시장은 종류와 치료법에 따라 분류됩니다. 유형별로 시장은 고셔병, 폼페병, 테이삭스병, 파브리병, 기타(시스틴증 및 크라베병)으로 분류됩니다. 한편, 치료별로는 효소보충요법, 기질감소치료, 줄기세포 이식으로 분류됩니다. 지역별로는 북미, 유럽, 아시아태평양, 기타 지역으로 분류됩니다. 북미는 리소좀 축적질환 시장에서 상당한 점유율을 차지할 것으로 예상되고 있습니다.

Actelion Pharmaceuticals, Ltd.(Johnson & Johnson Service, Inc.일부), BioMarin Pharmaceuticals, Inc, Eli Lilly Co., Horizon Therapeutics, Inc., Leadiant Biosciences, Inc., Pfizer, Inc., Sanofi S.A, Takeda Pharmaceuticals Co. Ltd.(은)가 리소좀 축적질환 시장에서 활동하는 주요 기업입니다. 이러한 기업은 리소좀 축적질환 치료법을 찾아내기 위해서 연구를 확대하고 있습니다. 또한 이러한 시장 기업은 합병이나 인수, 제휴, 연구개발 활동에 대한 투자 등의 성장 전략을 적극적으로 채용하여 세계 리소좀 축적질환 시장에서 경쟁력을 유지하고 있습니다.

세계의 리소좀 축적질환(Lysosomal Storage Disease) 시장을 조사했으며, 시장 개요, 시장 성장요인 및 저해요인 분석, 종류·치료법·지역별 시장 규모 추이와 예측, 경쟁 구도, 주요 기업 개요, 시장 기회 등의 정보를 전해드립니다.

목차

제1장 보고서 개요

제2장 시장 개요와 인사이트

  • 조사 범위
  • 애널리스트 인사이트와 현재 시장 동향
  • 규칙과 규제

제3장 경쟁 구도

  • 기업 점유율 분석
  • 주요 전략 분석
  • 주요 기업 분석
    • Pfizer, Inc.
    • Sanofi S.A.
    • Actelion Pharmaceuticals, Ltd.
    • Horizon Therapeutics, Inc.
    • Takeda Pharmaceuticals Co. Ltd.

제4장 시장 결정요인

  • 동기
  • 억제요인
  • 시장 기회

제5장 시장 세분화

  • 유형별
    • 고셔병
    • 폼페병
    • 테이삭스병
    • 파브리병
    • 기타(시스틴증, 크라베병)
  • 치료법별
    • 효소보충요법
    • 기질감소치료
    • 줄기세포 이식

제6장 지역 분석

  • 북미
    • 미국
    • 캐나다
  • 유럽
    • 영국
    • 독일
    • 이탈리아
    • 스페인
    • 프랑스
    • 기타 유럽
  • 아시아태평양
    • 중국
    • 인도
    • 일본
    • 기타 아시아태평양
  • 기타 지역

제7장 기업 개요

  • Actelion Pharmaceuticals, Ltd.(A Part of Johnson & Johnson Service, Inc.)
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics, Inc.
  • AMO Pharma, Ltd.
  • Arena Pharmaceuticals, Inc.
  • BioMarin Pharmaceuticals, Inc.
  • ChiesiFarmaceuticiSpA
  • Eli Lilly Co.
  • Horizon Therapeutics, Inc.
  • Leadiant Biosciences, Inc.
  • Pfizer, Inc.
  • ProtalixBioTherapeutics, Inc.
  • Sanofi S.A.
  • Sigilon Therapeutics, Inc.
  • Takeda PharmaceuticalsCo.Ltd.
LSH 20.08.12

LIST OF TABLES

  • 1. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 2. GLOBAL GAUCHER DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 3. GLOBAL POMPE DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 4. GLOBAL TAY-SACHS DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 5. GLOBAL FABRY DISEASE MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 7. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 8. GLOBAL ENZYME REPLACEMENT THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 9. GLOBAL SUBSTRATE REDUCTION THERAPYMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 10. GLOBAL STEM CELL TRANSPLANTMARKET RESEARCH AND ANALYSIS BY REGION, 2019-2026 ($ MILLION)
  • 11. GLOBAL LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2019-2026 ($ MILLION)
  • 12. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 15. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 16. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 17. EUROPEAN LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 18. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 19. ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 20. ASIA-PACIFIC LYSOSOMALSTORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)
  • 21. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 22. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL LYSOSOMAL STORAGE DISEASEMARKET SHARE BY TYPE, 2019 VS 2026 (%)
  • 2. GLOBAL LYSOSOMAL STORAGE DISEASEMARKET SHARE BY TREATMENT, 2019 VS 2026 (%)
  • 3. GLOBAL LYSOSOMAL STORAGE DISEASEMARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 4. US LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 5. CANADA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. UK LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. FRANCE LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. GERMANY LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. ITALY LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. SPAIN LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. ROE LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. INDIA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. CHINA LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. JAPAN LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. REST OF ASIA-PACIFIC LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF THE WORLD LYSOSOMAL STORAGE DISEASE MARKET SIZE, 2019-2026 ($ MILLION)

Global Lysosomal Storage Disease Market Size, Share & Trends Analysis Report by Type (Gaucher Disease, Pompe Disease, Tay-Sachs Disease, Fabry Disease, and Other (Cystinosis and Krabbe Disease)) by Treatment (Enzyme Replacement Therapy, Substrate Reduction Therapy, and Stem Cell Transplant) Forecast Period 2020-2026

Thelysosomal storage disease market is projected to grow at a considerable CAGR during the forecast period (2020-2026). The factors driving the growth of the market include the increasing rate of diagnosis of the disease, awareness about the disease and research and development in the healthcare sector. The diagnosis of the disease is difficult for physicians due to the variation of symptoms for different individuals. With more research and development going on, there is an improvement in the diagnosis of the disease. There are specialized lysosomal storage disease laboratories in which specific tests can be performed to diagnose the disease. This is fueling the growth of the market.

The lysosomal storage disease market is segmented on the basis of type and treatment. Based on the type, the market is segmented into Gaucher Disease, Pompe Disease, Tay-Sachs Disease, Fabry Disease, and other (Cystinosis and Krabbe Disease). Whereas, based on the treatment, the market is segmented into enzyme replacement therapy, substrate reduction therapy, and stem cell transplant. Geographically market is segmented into North America, Europe, Asia Pacific and the Rest of the World. North America is anticipated to hold a considerable share in the lysosmal storage disease market.

Actelion Pharmaceuticals, Ltd. (A Part of Johnson & Johnson Service, Inc.), BioMarin Pharmaceuticals, Inc, Eli Lilly Co., Horizon Therapeutics, Inc., Leadiant Biosciences, Inc., Pfizer, Inc., Sanofi S.A, and Takeda Pharmaceuticals Co. Ltd. among others are the key players operating in the lysosomal Storage disease market. These companies are expanding their researches to find a treatment for the lysosomal storage disease. Moreover, these market players are actively adopting growth strategies such as mergers and acquisitions, partnerships, investment in R&D activities among others to remain competitive in the global lysosomal storage disease market.

Research Methodology

The market study of the global lysosomal storage disease market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market.
  • Whitepapers, research-papers, and news blogs.
  • Company websites and their product catalog.

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for a 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation

1. Global Lysosomal Storage Disease Market Research and Analysis by Type

2. Global Lysosomal Storage Disease Market Research and Analysis byTreatment

The Report Covers:

  • Comprehensive research methodology of the global lysosomal storage disease market.
  • This report also includes a detailed and extensive market overview with key analyst insights.
  • An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global lysosomal storage disease market.
  • Insights about market determinants which are stimulating the global lysosomal storage disease market.
  • Detailed and extensive market segments with regional distribution of forecasted revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. Pfizer, Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Sanofi S.A.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Actelion Pharmaceuticals, Ltd.
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Horizon Therapeutics, Inc.
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Takeda Pharmaceuticals Co. Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Lysosomal Storage Disease Market by Type
    • 5.1.1. GaucherDisease
    • 5.1.2. Pompe Disease
    • 5.1.3. Tay-SachsDisease
    • 5.1.4. Fabry Disease
    • 5.1.5. Other (Cystinosis and Krabbe Disease)
  • 5.2. Global Lysosomal Storage Disease Market by Treatment
    • 5.2.1. Enzyme Replacement Therapy
    • 5.2.2. Substrate Reduction Therapy
    • 5.2.3. Stem Cell Transplant

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Actelion Pharmaceuticals, Ltd. (A Part of Johnson & Johnson Service, Inc.)
  • 7.2. Alexion Pharmaceuticals, Inc.
  • 7.3. Amicus Therapeutics, Inc.
  • 7.4. AMO Pharma, Ltd.
  • 7.5. Arena Pharmaceuticals, Inc.
  • 7.6. BioMarin Pharmaceuticals, Inc.
  • 7.7. ChiesiFarmaceuticiSpA
  • 7.8. Eli Lilly Co.
  • 7.9. Horizon Therapeutics, Inc.
  • 7.10. Leadiant Biosciences, Inc.
  • 7.11. Pfizer, Inc.
  • 7.12. ProtalixBioTherapeutics, Inc.
  • 7.13. Sanofi S.A.
  • 7.14. Sigilon Therapeutics, Inc.
  • 7.15. Takeda PharmaceuticalsCo.Ltd.
Back to Top
전화 문의
F A Q